Stanley Ho Centre for Emerging Infectious Diseases
Shatin, Hong Kong
NCT Number: NCT05781165
Objective: To apply augmented reality (AR) technology in HIV self-test and to assess its impacts in enhancing testing performance among men who have sex with men (MSM).
Design: Parallel randomised controlled, open label, trial. Block randomisation with a block size of 4 would be used to allocate the study arms.
Participants: men who have sex with men in Hong Kong
Intervention: Self-test assisted by AR vs self-test with instruction sheets
Main outcome measures: Effectiveness, usability, learnability, efficiency and satisfaction scores; rate of completion and result upload; acceptability of AR approach in assisting self-test
Anticipated results: 200 MSM would be recruited with 50 and 150 in control and intervention group, respectively. The scores in the intervention group are 10% higher than the control group. Proportion of satisfied participants in the intervention group is 10% more than the control group. AR approach is feasible and acceptable to MSM for assisting in HIV self-test.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
Shatin, Hong Kong
About 200 MSM would be recruited through community-based organisations and Internet channels where MSM socialise and seek partners. Fifty and 150 participants would be randomly assigned into the control and intervention group by block randomisation with a block size of 4, respectively. After giving informed consent, subjects would be invited to complete an online questionnaire and request for an HIV self-test kit in the online portal before randomisation. Participants in the control group would be given a standard commercially available self-test kit which included bilingual instruction sheets. Subjects in the intervention arm would be asked to use the AR element to assist the same standard commercially available self-test kit. All participants would be asked to upload the test result and complete a post-test questionnaire on the usability of the test and the AR approach. The result would be validated by an experienced research staff. Subjects with a positive result would be contacted for follow up. Main outcome measures in this study would include the confidence in performing the self-test and the usability of HIV self-testing between the two arms.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
Time frame: Month 3
Confidence in performing the self-test in a Likert scale of 1 (least confident) to 10 (most confident)
Time frame: Month 3
Score measured by system usability scale ranged from 0 to 100 (higher scores mean more usable)
Time frame: Month 3
Score measured by single ease question ranged from 1 to 7 (higher scores mean easier)
Time frame: Month 3
Score measured by after scenario questionnaire (average score of the 3-item questionnaire ranged from 1 to 7, higher scores mean more usable)
Time frame: Month 3
Score measured by subjective mental effort questionnaire ranged from 0 to 150 (higher scores mean more difficult)
Chinese University of Hong Kong
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03734393
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Birmingham, Alabama, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial DetailsNCT06139354
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05911360
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Phoenix, Arizona, United States
View Trial Details